BrainCool AB (publ): Change in terms and conditions in warrants of series TO1, TO2 and TO3
On April 8, 2020, BrainCool announced that the company is conducting a directed rights issue comprising 1,550,000 shares at a price of SEK 2,77 per share. As a result of the new shares being registered with Bolagsverket, there was a change in the terms of the warrants of series TO1, TO2 and TO3, as stated in §8 section 1.1 clause 11 of the terms. The change covers the strike price for all three series that now amounts to SEK 2,77. Otherwise, there are no changes in the terms and conditions. The conversion prices for the three series previously amounted to:
TO1 5,50 SEK
TO2 5,50 SEK
TO3 5,50 SEK
BrainCool's CEO, Martin Waleij comments;
We expect that the 3,247,335 outstanding options will contribute to the financing of the company and provide the company with SEK 9 million.
In the near future there are the following conversion periods:
TO3 conversion period August 24, 2020 - September 7, 2020
TO2 conversion period September 18, 2020 – October 2, 2020
TO1 conversion period November 20, 2020 – December 4, 2020
The terms and conditions for the warrants are listed as Appendix 1 and published on BrainCool's website: http://www.braincool.se/nyemission
For more information
Martin Waleij - CEO
+46 - 733 -93 70 76
E-mail: martin.waleij@braincool.se
About BrainCool AB (publ)
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.